1. Home
  2. NSPR vs ELUT Comparison

NSPR vs ELUT Comparison

Compare NSPR & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

N/A

Current Price

$0.76

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Logo Elutia Inc.

ELUT

Elutia Inc.

N/A

Current Price

$0.85

Market Cap

42.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSPR
ELUT
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
42.5M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
NSPR
ELUT
Price
$0.76
$0.85
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$6.00
AVG Volume (30 Days)
48.1K
44.0K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
146.77
EPS
N/A
N/A
Revenue
$2,310,000.00
$12,293,000.00
Revenue This Year
$57.98
N/A
Revenue Next Year
$95.41
$10.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.50
52 Week High
$2.57
$1.39

Technical Indicators

Market Signals
Indicator
NSPR
ELUT
Relative Strength Index (RSI) 42.04 45.16
Support Level $0.66 $0.51
Resistance Level $1.03 $1.03
Average True Range (ATR) 0.06 0.09
MACD -0.02 -0.01
Stochastic Oscillator 9.78 21.35

Price Performance

Historical Comparison
NSPR
ELUT

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Share on Social Networks: